Cargando…
High-dose olanzapine in treatment-resistant schizophrenia: a systematic review
BACKGROUND: Treatment-resistant schizophrenia (TRS) affects approximately 30% of people with schizophrenia. Clozapine is the gold standard treatment for TRS but is not always suitable, with a proportion of individuals intolerant of side effects or unable to engage in necessary blood monitoring. Give...
Autores principales: | Gannon, Louisa, Reynolds, John, Mahon, Martin, Gaughran, Fiona, Lally, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176543/ https://www.ncbi.nlm.nih.gov/pubmed/37187727 http://dx.doi.org/10.1177/20451253231168788 |
Ejemplares similares
-
Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
por: Lally, John, et al.
Publicado: (2016) -
High-dose olanzapine in treatment resistant schizophrenia. A case report and literature review
por: Clarke, Ciara, et al.
Publicado: (2021) -
Serum Prolactin and Bone Mineral Density in Schizophrenia: A Systematic Review
por: Lally, John, et al.
Publicado: (2019) -
Pathogenesis and management of Brugada syndrome in schizophrenia: A scoping review
por: Rastogi, Anuj, et al.
Publicado: (2020) -
Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)